HDB (HDB) Stock Price & Analysis
HDB (HDB) rose 1.22% to USD 23.29 as of June 10, 2026 at 00:28 UTC, according to Nexqual real-time market data.
HDB last closed at USD 23.01; the session ranged USD 23.2–23.42 on volume of 16,504,507 shares. Market capitalization is $119.54B, with a 52-week range of USD 22.91–39.81 (NYQ). Source: Nexqual, June 10, 2026 at 00:28 UTC.
Key Statistics (as of June 10, 2026 at 00:28 UTC)
| Price | USD 23.29 |
|---|---|
| Change | ▲ 1.22% (up) |
| Previous Close | USD 23.01 |
| Open | USD 23.31 |
| Day Range | USD 23.2 – 23.42 |
| 52-Week Range | USD 22.91 – 39.81 |
| Volume | 16,504,507 shares |
| Market Cap | $119.54B |
| Exchange | NYQ |
Technical Analysis (HDB)
Nexqual's technical model rates HDB "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:28 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.67 (neutral) |
| vs SMA50 | Below (USD 25.06) |
| MACD | -0.55 (negative) |
Analyst Ratings (HDB)
Wall Street analysts rate HDB "None" based on 4 analysts, with a mean price target of USD 34.43 (range USD 29.7–36), per Nexqual as of June 10, 2026 at 00:28 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 34.43 |
| High Target | USD 36 |
| Low Target | USD 29.7 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (HDB)
| Next Earnings Date | 2026-07-18 |
|---|---|
| EPS Estimate | USD 0.39 |
| Revenue Estimate | $471.12B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.4 vs est 0.39 ▲ beat |
| 2025-12-31 | USD 0.4 vs est 0.39 ▲ beat |
| 2025-09-30 | USD 0.41 vs est 0.36 ▲ beat |
| 2025-06-30 | USD 0.41 vs est 0.38 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:28 UTC.
Financials & Fundamentals (HDB)
| Total Revenue | $2.83T |
|---|---|
| Revenue Growth (YoY) | -1.80% |
| Gross Margin | +0.00% |
| Operating Margin | +40.54% |
| Profit Margin | +26.83% |
| ROE | +13.82% |
| Total Cash | $3.12T |
| Total Debt | $5.88T |
Source: Nexqual, June 10, 2026 at 00:28 UTC.
Financial Health Score (HDB)
Nexqual rates HDB's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:28 UTC.
| Growth | Critical — Revenue -33% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Gross margin 0% |
| Balance Sheet | Mixed — $3.12T cash vs $5.88T debt |
| Cash Flow | Weak — Operating cash flow -$2.75T |
| Efficiency | Mixed — ROE 14%, ROA 1.7% |
Ownership (HDB)
| Insider Ownership | +0.03% |
|---|---|
| Institutional Ownership | +13.53% |
| Shares Outstanding | 5.13B |
| Float | 25.56B |
| Short % of Float | +0.44% |
Source: Nexqual, June 10, 2026 at 00:28 UTC.
Leadership (HDB)
HDB is led by Sashidhar Jagdishan (age 60), MD, CEO & Director, per Nexqual as of June 10, 2026 at 00:28 UTC.
| MD, CEO & Director | Sashidhar Jagdishan (age 60) |
|---|---|
| Deputy MD & Director | Kaizad Maneck Bharucha (age 60) |
| Executive Whole-Time Director | Vedanthachari Srinivasa Rangan (age 65) |
| Chief Financial Officer | Srinivasan Vaidyanathan (age 60) |
Major Backers & Investors (HDB)
Notable institutional backers of HDB include Royal Bank of Canada, GQG Partners LLC, Morgan Stanley, according to Nexqual as of June 10, 2026 at 00:28 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Royal Bank of Canada | 0.83% |
| GQG Partners LLC | 0.66% |
| Morgan Stanley | 0.6% |
| Harding Loevner LP | 0.48% |
| Schroder Investment Management Group | 0.44% |
| JPMorgan | 0.36% |
| Principal Financial Group, Inc. | 0.35% |
| FIL LTD | 0.33% |
Source: Nexqual, June 10, 2026 at 00:28 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IBN | ICICI Bank Limited | USD 26.29 | ▲ 1.31% |
| RDY | Dr. Reddy's Laboratories Ltd | USD 13.37 | ▲ 0.98% |
| WIT | Wipro Limited | USD 2.16 | ▲ 2.86% |
| INFY | Infosys Limited | USD 12.24 | ▼ 1.29% |
| SAY | Saratoga Investment Corp 8.125% | USD 25.26 | ▼ 0.37% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:28 UTC. This page is informational and not investment advice.